The influence of cardiopulmonary bypass on cytokines and cell-cell communication

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 3, 1997, Pages 367-375

  Hill, Gary E ^a   Whitten, Charles W ^b   Landers, Dennis F ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NONE

Author keywords

cardiopulmonary bypass; cytokines; extracorporeal circulation

Indexed keywords

APROTININ; CORTICOTROPIN; CYTOCHROME P450; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; NITRIC OXIDE;

CARDIOPULMONARY BYPASS; CELL COMMUNICATION; COMPLEMENT ACTIVATION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; NEUTROPHIL CHEMOTAXIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SECRETION; REPERFUSION INJURY; REVIEW;

EID: 0030959956     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(97)90107-5     Document Type: Review

References (162)

1. Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 316:379-385, 1987
2. Dinarello CA: The interleukin family: 10 years of discovery. FASEB J 8:1314-1325, 1994
3. Billiau A, Vandederckhove F: Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 21:559-573, 1991
4. Dinarello CA, Gelfand JA, Wolff SM: Anti-cytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269:1829-1835, 1993
5. Casey LC: Roles of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg 56:s92-s96, 1993
6. Llamas R, Forthman HJ: Respiratory distress syndrome in the adult after cardiopulmonary bypass. JAMA 225:1183-1186, 1973
7. Jansen NJG, van Oeveren W, Gu YJ, et al: Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54:744-748, 1992
8. Hoffman WD, Natanson C: Endotoxin in septic shock. Anesth Analg 77:613-624, 1993
9. Andersen LW, Landow L, Baek L, et al: Association between gastric intramucosal pH and splanchnic endotoxin, antibody to endotoxin, and tumor necrosis factor-α concentrations in patients undergoing cardiopulmonary bypass. Crit Care Med 21:210-217, 1993
10. Tao W, Zwischenberger JB, Nguyen TT, et al: Gut mucosal ischemia during normothermic cardiopulmonary bypass results from blood flow redistribution and increased oxygen demand. J Thorac Cardiovasc Surg 110:819-828, 1995
11. Oudemans-van Straaten HM, Jansen PGM, Hoek FJ, et al: Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients. J Cardiothorac Vasc Anesth 10:187-194, 1996
12. Martinez-Pellus AE, Merino P, Bru M, et al: Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass? Crit Care Med 21:1684-1691, 1993
13. Schumann RR, Leong SR, Flaggs GW, et al: Structure and function of lipopolysaccharide binding protein. Science 249:1429-1431, 1990
14. Wright SD, Ramos RA, Tobias PS, et al: CD14, a receptor for complexes of lipopolysaccharide (LPS) binding protein. Science 249: 1431-1433, 1990
15. Dinarello CA, Cannon JG, Wolff SM, et al: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 163:1433-1450, 1986
16. Schindler R, Mancilla J, Endres S, et al: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40-47, 1990
17. Lowry SF: Cytokine mediators of immunity and inflammation. Arch Surg 128:1235-1241, 1993
18. Journois D, Pouard P, Greeley WJ, et al: Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Anesthesiology 81:1181-1189, 1994
19. Menasché P, Haydar S, Peynet J, et al: A potential mechanism of vasodilation after warm heart surgery. J Thorac Cardiovasc Surg 107:293-299, 1994
20. Teoh KHT, Bradley CA, Gauldie J, et al: Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 92:11347-11353, 1995 (suppl II)
21. Haeffner-Cavaillon N, Roussellier N, Ponzio O, et al: Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 98:1100-1106, 1989
22. Tulla H, Takala J, Alhava E, et al: Hypermetabolism after coronary artery bypass. J Thorac Cardiovasc Surg 101:598-600, 1991
23. Hennein HA, Ebba H, Rodriguez JL, et al: Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 108:626-635, 1994
24. Kimmel SC, van de Stouwe MJ, Levin RI, et al: A final common pathway for anti-inflammatory agents: Inhibition of leukocyteendothelial interactions. Trans Assoc Am Physicians 104:113-124, 1991
25. Carlos TM, Harlan JM: Membrane proteins involved in phagocyte adherence to endothelium. Immunol Rev 114:5-28, 1990
26. Hughes BJ, Hollers JC, Crockett-Torabi E, et al: Recruitment of CDllb/CD18 to the neutrophil surface and adherence-dependent cell locomotion. J Clin Invest 90:1687-1696, 1992
27. Springer TA: Adhesion receptors of the immune system. Nature 346:425-434, 1990
28. Arnaout MA: Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75:1037-1050, 1990
29. Osborn L: Leukocyte adhesion to endothelium in inflammation. Cell 62:3-6, 1990
30. Luscinskas FW, Cybulsky MI, Kiely J, et al: Cytokine-activated human endothelial monolayers support enhanced neutrophil transmigration via a mechanism involving both endothelial-leukocyte adhesion molecule-1 and intercellular adhesion molecule-1. J Immunol 146:1617-1625, 1991
31. Kukielka GL, Smith CW, Manning AM, et al: Induction of interleukin-6 synthesis in the myocardium. Circulation 92:1866-1875, 1995
32. Kilbride PM, Mayer JE, Newberger JW, et al: Induction of intercellular adhesion molecule-1- and E-selection mRNA in heart and skeletal muscle of pediatric patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 107:1183-1192, 1994
33. Hill GE, Alonso A, Thiele GM, et al: Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 79:23-27, 1994
34. Gillinov AM, Bator JM, Zehr KJ, et al: Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 56:847-853, 1993
35. Menasché P, Peynet J, Lariviere J, et al: Does normothermia during cardiopulmonary bypass increase neutrophil-endothelium interactions? Circulation 90:11275-11279, 1994
36. Boldt J, Osmer C, Linke LC, et al: Circulating adhesion molecules in pediatric cardiac surgery. Anesth Analg 81:1129-1135, 1995
37. Leeuwenberg JFM, Smeets EF, Neefjes JJ, et al: E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543-549, 1992
38. Johnson D, Thompson D, Hurst T, et al: Neutrophil-mediated acute lung injury after extracorporeal circulation. J Thorac Cardiovasc Surg 107:1193-1202, 1994
39. Dreyer WJ, Michael LH, Nguyen T, et al: Neutrophil-mediated pulmonary injury in a canine model of cardiopulmonary bypass: Evidence for a CD18-dependent mechanism. Circulation 86:2502, 1992
40. Gillinov AM, Redmond JM, Zehr KJ, et al: Inhibition of neutrophil adhesion during cardiopulmonary bypass. Ann Thorac Surg 57:126-133, 1994
41. Wilson I, Gillinov AM, Curtis WE, et al: Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart. Circulation 88:372-379, 1993
42. Byrne JG, Smith WJ, Murphy MP, et al: Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion. J Thorac Cardiovasc Surg 104:1589-1596, 1992
43. Simpson PJ, Todd RF, Fantone JC, et al: Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (Anti-Mo1, Anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest 81:624-629, 1988
44. Entman ML, Youker KA, Shojit T, et al: Neutrophil-induced oxidative injury of cardiac myocytes: A compartmented system requiring CD11b/CD18-ICAM-1 adherence. J Clin Invest 90:1335-1345, 1992
45. Smith CW, Entman ML, Lance CL, et al: Adherence of neutrophils to canine cardiac myocytes in vitro is dependent on intercellular adhesion molecule-1. J Clin Invest 88:1216-1223, 1991
46. Simon RH, DeHart PD, Todd RF: Neutrophil-induced injury of rat pulmonary alveolar epithelial cells. J Clin Invest 78:1375-1386, 1986
47. Craddock PR, Fehr J, Brigham KL, et al: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296:769-774, 1977
48. Pearse DB, Sylvester JT: Vascular injury in isolated sheep lungs. Am J Respir Crit Care Med 153:196-202, 1996
49. Weyrich AS, Ma X, Lefer DJ, et al: In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest 91:2620-2629, 1993
50. Larsen E, Celi A, Gilbert GE, et al: PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 59:305-312, 1989
51. Rinder CS, Bohnert J, Rinder HM, et al: Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 75:388-393, 1991
52. Hamburger SA, McEver RP: GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 75:550-554, 1990
53. Todoroki N, Watanabe Y, Akaike T, et al: Enhancement by IL-1β and IFN-γ of platelet activation: Adhesion to leukocytes via GMP-140/PADGEM protein (CD62). Biochem Biophys Res Commun 179:756-761, 1991
54. Rajagopalan V, Essex DW, Shapiro SS, et al: Tumor necrosis factor-a modulation of glycoprotein Ibα expression in human endotheα lial and erythroleukemia cells. Blood 80:153-161, 1992
55. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012, 1993
56. Belvisi MG, Stretton CD, Yacoub M, et al: Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur J Pharm 210:221-222, 1992
57. Kubes P, Suzuki M, Granger DN: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci 88:4651-4655, 1991
58. Alican I, Kubes P: A critical role for nitric oxide in intestinal barrier function and dysfunction. Am J Physiol 270:G225-G237, 1996
59. Wink DA, Kasprzak KS, Maragos CM, et al: DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254:1001-1003, 1991
60. Radi R, Beckman JS, Bush KM, Freeman BA: Peroxynitrite oxidation of sulfhydryls. J Biol Chem 266:4244-4250, 1991
61. Nijkamp FP, Folkerts G: Nitric oxide and bronchial reactivity. Clin Exp Allergy 24:905-914, 1994
62. Kuo H, Liu S, Barnes PJ: The effect of endogenous nitric oxide on neurogenic plasma exudation in guinea-pig airways. Eur J Pharm 221:385-388, 1992
63. Berisha H, Pakbaz H, Absood A, et al: Nitric oxide as a mediator of oxidant lung injury due to paraquat. Proc Natl Acad Sci USA 91:1-5, 1994
64. Folkerts G, Henricks PAJ, Slootweg PJ, et al: Endotoxin-induced inflammation and injury of the guinea pig respiratory airways cause bronchial hyporeactivity. Am Rev Respir Dis 137:1441-1448, 1988
65. Finkel MS, Oddis CV, Jacob TD, et al: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257:387-389, 1992
66. Doss DN, Estafanous FG, Ferrario CM, et al: Mechanisms of systemic vasodilation during normovolemic hemodilution. Anesth Analg 81:30-34, 1995
67. Matheis G, Sherman MP, Buckberg GD, et al: Role of 1-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol 262:H616-H620, 1992
68. Depre C, Vanoverschelde J, Goudemant J, et al: Protection against ischemic injury by nonvasoactive concentrations of nitric oxide sythase inhibitors in the perfused rabbit heart. Circulation 92:1911-1918, 1995
69. Ma TT, Ischiropoulos H, Brass CA: Endotoxin-stimulated nitric oxide production increases injury and reduces rat liver chemiluminescence during reperfusion. Gastroenterology 108:463-469, 1995
70. Boughton-Smith NK, Evans SM, Laszlo F, et al: The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol 110:1189-1195, 1993
71. Thiemermann C, Wu CC, Piper J, et al: Aminoguanidine attenuates the delayed circulatory failure in endotoxin and haemorrhagic shock in the anesthetized rat. Can J Physiol Pharmacol 72: P14.2.22, 1994 (suppl I)
72. Fukuda H, Sawa Y, Kadoba K, et al: Supplement of nitric oxide attenuates neutrophil mediated reperfusion injury. Circulation 92:11413-11416, 1995 (suppl II)
73. Ma X, Weyrich AS, Lefer DJ, Lefer AM: Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 72:403-412, 1993
74. Ignarro LJ, Fukuto JM, Griscavage JM, et al: Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric oxide from I-arginine. Proc Natl Acad Sci USA 90:8103-8107, 1993
75. Ruvolo G, Greco E, Speziale G, et al: Nitric oxide formation during cardiopulmonary bypass. Ann Thorac Surg 57:1055-1056, 1994
76. +2-independent nitric oxide synthase activity in human lung after cardiopulmonary bypass. Thorax 50:403-404, 1995
77. Kobzik L, Bredt DS, Lowenstein CJ, et al: Nitric oxide synthase in human and rat lung: Immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 9:371-377, 1993
78. Hill GE, Snider S, Galbraith T, et al: Glucocorticoids reduce bronchial epithelial inflammation during cardiopulmonary bypass. Am J Respir Crit Care Med 152:1791-1795, 1995
79. Massaro AF, Gaston B, Kita D, et al: Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 152:800-803, 1995
80. Barnes PJ, Belvisi MG: Nitric oxide and lung disease. Thorax 48:1034-1043, 1993
81. McGowan FX, Ikegami M, del Nido PJ, et al: Cardiopulmonary bypass significantly reduces surfactant activity in children. J Thorac Cardiovasc Surg 106:968-977, 1993
82. Macnaughton PD, Braude S, Hunter DN, et al: Changes in lung function and pulmonary capillary permeability after cardiopulmonary bypass. Crit Care Med 20:1289-1294, 1992
83. Roeise O, Garred P, Mollness TE, et al: Studies on the dose dependence of endotoxin-induced in vitro activation of the complement system. Eur Surg Res 21:34-41, 1989
84. Clardy CW: Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B. Infect Immun 62:4549-4555, 1994
85. van Deventer SJH, Hack CE, Wolbink CE, et al: Endotoxin-induced neutrophil activation: The role of complement revisited. Prog Clin Biol Res 367:101-109, 1991
86. Grisham MB, Everse J, Janssen HF: Endotoxemia and neutrophil activation in vivo. Am J Physiol 254:H1017-H1022, 1988
87. Burrell R: Immunomodulation by bacterial endotoxin. Crit Rev Microbiol 17:189-208, 1990
88. Witthaut R, Farhood A, Smith CW, et al: Complement and tumor necrosis factor-alpha contribute to Mac-1 (CD11b/CD18) up-regulation and systemic neutrophil activation during endotoxemia in vivo. J Leukoc Biol 55:105-111, 1994
89. Okusawa S, Dinarello CA, Yancey KB, et al: C5a induction of human interleukin-1 synergistic effect with endotoxin or interferon-gamma. J immunol 139:2635-2640, 1987
90. Homeister JW, Satoh P, Lucchesi BR: Effects of complement activation in the isolated heart. Circ Res 71:303-319, 1992
91. Cavarocchi NC, Pluth JR, Schaff HV, et al: Complement activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 91:252-258, 1986
92. Steinberg JB, Kapelanski DP, Oison JD, et al: Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 106:1008-1016, 1993
93. Jansen PGM, Velthuis H, Huybregts RA, et al: Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 110:829-834, 1995
94. Niazi Z, Flodin P, Joyce L, et al: Effects of glucocorticoids in patients undergoing coronary artery bypass surgery. Chest 76:262-268, 1979
95. Andersen LW, Baek L, Thomsen BS, et al: The effect of methylprednisolone on endotoxemia and complement activation during cardiac surgery. J Cardiothorac Anesth 3:544-549, 1989
96. Hill GE, Alonso A, Spurzem JR, et al: Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110:1658-1662, 1995
97. Jansen NJG, van Oeveren W, Borek LVD, et al: Inhibition of dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg 102:515-525, 1991
98. Jansen NJG, van Oeveren W, van Vliet M, et al: The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Eur J Cardiothorac Surg 5:211-217, 1991
99. Barber AE, Coyle SM, Fong Y, et al: Impact of hypercortisolemia on the metabolic and hormonal responses to endotoxin in humans. Surg Forum 41:74-77, 1990
100. Rock CS, Coyle SM, Keogh CV, et al: Influence of hypercortisolemia on the acute-phase protein response to endotoxin in humans. Surgery 112:467-474, 1992
101. Huang ZB, Eden E: Effect of corticosteroids on IL1β and TNFα release by alveolar macrophages from patients with AIDS and pneumocystis carinii pneumonia. Chest 104:751-755, 1993
102. Redl H, Lamche H, Paul E, et al: Effect of methylprednisolone, prednisolone, and dexamethasone on granulocyte function and complement activation. Prog Clin Biol Res 2366:261-272, 1987
103. Zitnik RJ, Whiting NL, Elias JA: Glucocorticoid inhibition of interleukin-1 induced interleukin-6 production by human lung fibroblasts: Evidence for transcriptional and post-transcriptional regulatory mechanism. Am J Respir Cell Mol Biol 10:643-650, 1994
104. Cronstein BN, Kimmel SC, Levin RI, et al: A mechanism for the antiinflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 89:9991-9995, 1992
105. Radomski MW, Palmer RMJ, Moncada S: Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 87:10043-10047, 1990
106. Knowles RG, Salter M, Brooks SL, et al: Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver, and aorta of the rat. Biochem Biophys Res Commun 172:1042-1048, 1990
107. Rees DD, Cellek S, Palmer RMJ, et al: Dexamethasone prevents the induction of a nitric oxide synthase and the associated effects on vascular tone: An insight into endotoxin shock. Biochem Biophys Res Commun 173:541-547, 1990
108. Kharitonov SA, Yates DH, Barnes PJ: Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 153:454-457, 1996
109. Bidstrup BP, Royston D, Sapsford RN, et al: Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97:364-672, 1989
110. Trapnell JE, Rigby CC, Talbot CH, et al: A controlled trial of trasylol in the treatment of acute pancreatitis. Br J Surg 61:177-182, 1974
111. Ogata H, Kim S, Fukazawa T, et al: The effects of aprotinin on the phagocytic activity of the reticulo-endothelial system and plasma prekallikrein levels during endotoxin shock. Prog Clin Biol Res 111:309-322, 1983
112. Schlag G, Redl H: The proteinases in shock. Resuscitation 14:3-21, 1986
113. McMichan JC, Rosengarten DS, Phillipp E: Prophylaxis of post-traumatic pulmonary insufficiency by proteinase inhibitor therapy with aprotinin: A clinical study. Circ Shock 9:107-116, 1982
114. Janoff A: Elastase in tissue injury. Annu Rev Med 36:207-216, 1985
115. Welbourn CRB, Goldman G, Paterson IS, et al: Neutrophil elastase and oxygen radicals: Synergism in lung injury after hindlimb ischemia. Am J Physiol 260:H1852-H1856, 1991
116. Nishiyama T, Aibiki M, Hanaoka K: The effect of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymorphonuclear granulocyte elastase. Anesth Analg 82:108-112, 1996
117. Sakamaki F, Ishizaka A, Urano T, et al: Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am J Respir Crit Care Med 153:391-397, 1996
118. Hughes B, Parratt JR: The effects of the protease inhibitor, aprotinin, on the course of shock induced by endotoxin in cats. Br J Pharmacol 86:399-403, 1985
119. Swartholm E, Haglund U, Ljungberg J, et al: Influence of aprotinin, a protease inhibitor, on porcine E. coli shock. Acta Chir Scand 155:7-13, 1989
120. Camussi G, Tetta C, Bussolino F, et al: Synthesis and release of platelet-activating factor is inhibited by plasma α1-proteinase inhibitor or α1-antichymotrypsin and is stimulated by proteinase. J Exp Med 168:1293-1306, 1988
121. Szabo C, Wu C, Mitchell JA, et al: Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 73:991-999, 1993
122. Aoki M, Jonas RA, Nomura F, et al: Effects of aprotinin on acute recovery of cerebral metabolism in piglets after hypothermic circulatory arrest. Ann Thorac Surg 58:146-153, 1994
123. Hunyadi J, Kenderessy AS, Duda E, et al: Platelet-activating factor antagonists (BN 52021 and BN 50730) inhibit tumor necrosis factor-alpha-mediated cytotoxicity on murine L929 tumor cells. Mol Immunol 30:517-519, 1993
124. Kim KU, Kwon OJ, Jue DM: Pro-tumour necrosis factor cleavage enzyme in macrophage membrane/particulate. Immunology 80:134-139, 1993
125. Whitten CW, Latson TW, Allison PM, et al: Does aprotinin inhibit cardiopulmonary bypass-induced inflammation? Anesthesiology 77:A266, 1992
126. Wachtfogel YT, Kucich U, Hack CE, et al: Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106:1-9, 1993
127. Lord RA, Roath OS, Thompson JF, et al: Effect of aprotinin on neutrophil function after major vascular surgery. Br J Surg 79:517-521, 1992
128. Nishijima J, Hiraoka N, Murata A, et al: Protease inhibitors (gabexate mesylate and ulinastatin) stimulate intracellular chemiluminescence in human neutrophils. J Leukoc Biol 52:262-268, 1992
129. Sawa Y, Shimazaki Y, Kadoba K, et al: Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J Thorac Cardiovasc Surg 111:29-35, 1996
130. Wendel HP, Heller W, Michel J, et al: Lower cardiac tropinin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 109:1164-1172, 1995
131. Kim H, Lee HS, Chang KT, et al: Chloromethyl ketones block induction of nitric oxide synthase in murine macrophages by preventing activation of nuclear factor-κB. J Immunol 154:4741-4748, 1995
132. Royston D: Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J Cardiovasc Pharmacol 27:542-549, 1996 (suppl 1)
133. Shakhov AN, Collart MA, Vassalli P, et al: κB-type enhancers are involved in kipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J Exp Med 171:35-47, 1990
134. Tumen, J, Meyrick B, Berry L, et al: Antiproteases protect cultured lung endothelial cells from endotoxin injury. J Appl Physiol 65:835-843, 1988
135. Kilbourn RG, Belloni P: Endothelial cell production of nitrogen oxides in response to IFN in combination with TNF, IL-1, or endotoxin. J Natl Cancer Inst 82:772-776, 1990
136. Radomski MW, Palmer RMJ, Moncada S: The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 148:1482-1489, 1987
137. Menasché P, Peynet J, Haeffner-Cavaillon N, et al: Influence of temperature on neutrophil trafficking during clinical cardiopulmonary bypass. Circulation 92:11334-11340, 1995 (suppl II)
138. Le Deist F, Menasché P, Kucharski C, et al: Hypothermia during cardiopulmonary bypass delays but does not prevent neutrophilendothelial cell adhesion. Circulation 92:II354-II358, 1995 (suppl II)
139. Redmond JM, Gillinov AM, Stuart S, et al: Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg 56:474-479, 1993
140. Morioka K, Muraoka R, Chiba Y, et al: Leukocyte and platelet depletion with a blood cell separator: Effects of lung injury after cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg 111:45-54, 1996
141. Steinberg BM, Grossi EA, Schwartz DS, et al: Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 60:525-529, 1995
142. Jansen PGM, te Velthuis H, Huybregts RAJM, et al: Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 110:829-834, 1995
143. Naik SK, Knight A, Elliott M: A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery. Circulation 84:422-431, 1991
144. Elliott MJ: Ultrafiltration and modified ultrafiltration in pediatric open heart operations. Ann Thorac Surg 56:1518-1522, 1993
145. Millar AB, Armstrong L, van der Linden J, et al: Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 56:1499-1502, 1993
146. Mink SN, Jha P, Wang R, et al: Effect of continuous arteriovenous hemofiltration combined with systemic vasopressor therapy on depressed left ventricular contractility and tissue oxygen delivery in canine Escherichia coli sepsis. Anesthesiology 83:178-190, 1995
147. Vincent JL, Tielemans C: Continuous hemofiltration in severe sepsis: Is it beneficial? J Crit Care 10:27-32, 1995
148. Mathew JP, Rinder CS, Tracey JB, et al: Acadesine inhibits neutrophil CD11b upregulation in vitro and during in vivo cardiopulmonary bypass. J Thorac Cardiovasc Surg 109:448-456, 1995
149. Galinanes M, Bullough D, Mullane K, et al: Sustained protection by acadesine against ischemia and reperfusion-induced injury. Circulation 86:589-597, 1992
150. Olafsson B, Forman MB, Puett DW, et al: Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: Importance of the endothelium and the no-reflow phenomenon. Circulation 76:1135-1145, 1987
151. Cronstein B, Levin R, Belnoff J, et al: Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin Invest 78:760-770, 1986
152. Gruber H, Hoffer M, McAllister D, et al: Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: Effects on flow, granulocytes, and injury. Circulation 80:1400-1411, 1989
153. Stewart AG, Harris T: Adenosine inhibits platelet-activating factor, but not tumor necrosis factor-α-induced priming of human neutrophils. Immunology 78:152-158, 1993
154. Cronstein BN, Van de Stouwe M, Druska L, et al: Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: Adenosine dependent and independent mechanisms. Inflammation 18:323-335, 1994
155. Leung JM, Stanley T, Mathew J, et al: An initial, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. Anesth Analg 78:420-434, 1994
156. Lane TA, Larrikin GE: Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Blood 68:351-354, 1986
157. Babbitt DG, Forman MB, Jones R, et al: Prevention of neutrophil-mediated injury to endothelial cells by perfluorochemical. Am J Pathol 136:451-459, 1990
158. Smith DJ, Lane TA: Effect of a high concentration perflubron emulsion on platelet function. Biomater Art Cells Immob Biotech 21:173-181, 1993
159. Vercellotti GM, Hammerschmidt DE, Craddack PR, Jacob HS: Activation of plasma complement by perfluorocarbon artificial blood: Probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis. Blood 59:1299-1304, 1982
160. Naccache PH, Jean N, Liao NW, et al: Regulation of stimulated integrin surface expression in human neutrophils by tyrosine phosphorylation. Blood 84:616-624, 1994
161. Kaneko T, Jorens PG, Richman-Eisenstat JB, et al: Leumedin NPC 15669 inhibits antigen-induced recruitment of inflammatory cells into the canine airways. Am J Physiol 267:L250-L255, 1994
162. Burch RM, Noronha-Blob L, Bator JM, et al: Mice treated with a leumedin or antibody to Mac-1 to inhibit leukocyte sequestration survive endotoxin challenge. J Immunol 150:3397-3403, 1993